Intervention
SKB264
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 16 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
16 shownMulticenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast CancerNCT07371208 · 2025-12-24
RECRUITINGA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyNCT07071337 · 2025-07-18
RECRUITINGA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerNCT06279364 · 2024-02-28
RECRUITINGStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerNCT06081959 · 2023-10-31
RECRUITINGSKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.NCT05351788 · 2022-05-20
RECRUITINGEfficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver MetastasisNCT07545213 · 2026-04-20
NOT_YET_RECRUITINGStudy of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNCT07466927 · 2026-03-15
NOT_YET_RECRUITINGHIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast CancerNCT06849492 · 2025-04-01
NOT_YET_RECRUITINGA Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06670196 · 2024-11-27
ACTIVE_NOT_RECRUITINGA Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06711900 · 2024-10-30
ACTIVE_NOT_RECRUITINGA Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06448312 · 2024-06-07
ACTIVE_NOT_RECRUITINGA Phase III Study of SKB264 for EGFR Mutant NSCLC PatientsNCT05870319 · 2023-06-26
ACTIVE_NOT_RECRUITINGA Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)NCT05816252 · 2023-04-19
ACTIVE_NOT_RECRUITINGSKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerNCT05445908 · 2022-08-17
COMPLETEDSKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerNCT05347134 · 2022-06-10
ACTIVE_NOT_RECRUITINGPhase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)NCT04152499 · 2020-02-28
ACTIVE_NOT_RECRUITINGCommon conditions
Non-small Cell Lung Cancer8Breast Cancer2Metastatic Breast Cancer2Triple Negative Breast Cancer2Advanced Triple Negative Breast Cancer1Cervical Cancer1EGFR Mutant Advanced Non-small Cell Lung Cancer1Endometrial Carcinoma1Epithelial Ovarian Cancer1Gastric Adenocarcinoma1Gastroesophageal Junction Adenocarcinoma1Head and Neck Squamous Cell Carcinoma1HER2-negative Breast Cancer1Small-Cell Lung Cancer1Triple-negative Breast Cancer and HR+/HER2- BC1Urothelial Carcinoma1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING7
RECRUITING5
NOT_YET_RECRUITING3
COMPLETED1
Phase mix
PHASE28
PHASE38
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.